Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
Konstas Anastasios G P, Kozobolis Vassilios P, Tsironi Sevasti, Makridaki Irene, Efremova Rallitsa, Stewart William C
AI Summary
This study compared latanoprost and dorzolamide/timolol fixed combination, finding both had similar 24-hour IOP-lowering efficacy after six months, despite minor differences in side effects.
Abstract
Purpose
To evaluate the 24-hour intraocular pressure (IOP)-lowering effect of latanoprost and the dorzolamide/timolol fixed combination (DTFC) after 2 and 6 months of treatment.
Design
Randomized, prospective, crossover comparison.
Participants
Thirty-nine patients had primary open-angle glaucoma, and 14 patients had ocular hypertension.
Methods
After a 6-week washout period, patients were randomized to either 6 months of treatment with the DTFC twice daily or latanoprost every evening and then crossed over to the opposite treatment for an additional 6 months.
Main outcome measure: Mean 24-hour IOP after 2 and 6 months of treatment.
Results
Fifty-three patients had an average 24-hour baseline IOP of 25.2+/-2.3 mmHg. After 6 months of treatment, 24-hour IOPs were 18.1+/-1.9 mmHg for the DTFC and 18.3+/-1.9 mmHg for latanoprost. Compared with 2 months of therapy, at 6 months the DTFC showed no significant change in mean 24-hour IOP, whereas latanoprost demonstrated a reduction of 0.3 mmHg (P = 0.01). The DTFC had more burning (P<0.001) and bitter taste (P = 0.01), whereas the latanoprost had more hypertrichosis (P = 0.02).
Conclusions
After 6 months of therapy, the DTFC and latanoprost have clinically similar 24-hour IOP-lowering efficacies.
MeSH Terms
Shields Classification
Related Articles5
Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis.
Systematic ReviewA phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.
Randomized Controlled TrialPhase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Randomized Controlled TrialThe Effect of Latanoprostene Bunod 0.024% on Optical Coherence Tomography Angiography in Newly Diagnosed Open Angle Glaucoma.
Clinical TrialAqueous Humor Dynamics Changes and Predictors of IOP Response to Latanoprost in Healthy Subjects.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.